Mammography News: FDA Clears AI Software for Breast Arterial Calcification Detection
Utilized in conjunction with screening digital mammography or digital breast tomosynthesis (DBT), the artificial intelligence (AI)-powered software cmAngio may help detect and localize breast arterial calcification (BAC), an incidental finding that has been linked to an elevated risk for heart disease and stroke.
The Food and Drug Administration (FDA) has granted 510(k) clearance for cmAngio®, an artificial-intelligence (AI)-enabled software that facilitates the detection of breast arterial calcification (BAC) through assessment of full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT).1
While BAC is a common incidental finding on mammograms, less than 5 percent of BAC are reported, according to CureMetrix, the developer of cmAngio. A recent study found that postmenopausal women with BAC detected on mammography exams are 51 percent more likely to have a stroke or develop heart disease.2
“There is a growing consensus among the medical community that the presence of breast arterial calcifications should be included on mammogram reports,” said Lisa Watanabe, M.D., FACR, the chief medical officer at CureMetrix. “The cmAngio software will be a tremendous aid for radiologists like myself in providing timely and accurate results for BAC detection. I am hopeful that cmAngio will someday be widely incorporated in breast imaging practices as a useful application of artificial intelligence that can enhance physician decision-making, reporting, and patient care."
CureMetrix emphasized that cmAngio facilitates identification and reporting of BAC without additional procedures and increased radiation risk for patients. The AI software has demonstrated efficacy for women of varying breast density, according to CureMetrix.
The company adds that cmAngio is compatible with DICOM-compatible viewers and can be installed in less than an hour.
References
1. CureMetrix. CureMetrix receives FDA clearance for cmAngio®, first-of-its-kind solution for detecting breast arterial calcification. EIN Presswire. Available at: https://www.einpresswire.com/article/661554753/curemetrix-receives-fda-clearance-for-cmangio-first-of-its-kind-solution-for-detecting-breast-arterial-calcification#:~:text=SAN%20DIEGO%2C%20CA%2C%20UNITED%20STATES,BAC)%20detection%20and%20localization%20software. Published October 16, 2023. Accessed October 17, 2023.
2. Iribarren C, Chandra M, Lee C, et al. Breast arterial calcification: a novel cardiovascular risk enhancer among postmenopausal women. Circ Cardiovasc Imaging. 2022;15(3):e013526.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
